Trial Profile

A Phase I/II Clinical Study of JS004, a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA), in Subjects With Head and Neck Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tifcemalimab (Primary) ; Toripalimab (Primary)
Indications Carcinoma; Head and neck cancer; Nasopharyngeal cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Shanghai Junshi Biosciences

Most Recent Events

27 Jul 2023 Status changed from recruiting to completed.
25 Feb 2022 Number of treatment arms increased from 2 to 4. Toripalimab (JS001) has been introduced in the treatment and will be given in combination with JS004 in arm 3 and 4.Accordingly, the planned number of patients increased from 60 to 149.
25 Feb 2022 Planned number of patients changed from 60 to 149.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com